Literature DB >> 19430822

An ab initio quantum mechanical drug designing procedure: application to the design of balanced dual ACE/NEP inhibitors.

Nishi K Rao1, Arpita Yadav, Sanjeev Kumar Singh.   

Abstract

This article describes in a sequential fashion how ab initio quantum mechanical methods can be applied to study the pharmacophoric features of drugs. It also describes how accurate drug-receptor interaction calculations can guide the careful design of balanced dual inhibitors, which form an important class of second generation drugs. As an example, the authors have chosen balanced inhibitors of angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) as modern antihypertensive drugs. A unified, accurate, in silico design approach is presented, encompassing all steps from pharmacophore derivation to complete understanding of mechanistic aspects leading to drug design.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430822     DOI: 10.1007/s00894-009-0500-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  28 in total

Review 1.  Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics.

Authors:  Giuseppe Molinaro; Jean-Lucien Rouleau; Albert Adam
Journal:  Curr Opin Pharmacol       Date:  2002-04       Impact factor: 5.547

2.  An ab initio study of AT2 antagonists.

Authors:  Swati Jain; Arpita Yadav
Journal:  Chem Biol Drug Des       Date:  2008-01-31       Impact factor: 2.817

Review 3.  Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists.

Authors:  C I Johnston; P G Hodsman; M Kohzuki; D J Casley; B Fabris; P A Phillips
Journal:  Am J Med       Date:  1989-12-26       Impact factor: 4.965

Review 4.  Angiotensin-converting enzyme inhibitors: past, present, and bright future.

Authors:  C R Edwards; P L Padfield
Journal:  Lancet       Date:  1985-01-05       Impact factor: 79.321

5.  Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding.

Authors:  C Marie-Claire; E Ruffet; S Antonczak; A Beaumont; M O'Donohue; B P Roques; M C Fournié-Zaluski
Journal:  Biochemistry       Date:  1997-11-11       Impact factor: 3.162

6.  Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.

Authors:  S Laurent; P Boutouyrie; M Azizi; C Marie; C Gros; J C Schwartz; J M Lecomte; J Bralet
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

Review 7.  Vasopeptidase inhibitors.

Authors:  Giuseppe A Sagnella
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2002-06       Impact factor: 1.636

Review 8.  Antihypertensive effect of perindopril: experimental pharmacology.

Authors:  M Barthelmebs; M Devissaguet; J L Imbs
Journal:  Clin Exp Hypertens A       Date:  1989

9.  Structural analysis of neprilysin with various specific and potent inhibitors.

Authors:  Christian Oefner; Bernard P Roques; Marie-Claude Fournie-Zaluski; Glenn E Dale
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-01-23

Review 10.  Ace revisited: a new target for structure-based drug design.

Authors:  K Ravi Acharya; Edward D Sturrock; James F Riordan; Mario R W Ehlers
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.